Type 2 diabetes patients taking SGLT-2 inhibitors have lower levels of uric acid in their blood than those on other diabetes medications.

Scientific Claim

In patients with type 2 diabetes, SGLT-2 inhibitor use is associated with lower circulating uric acid levels compared to other glucose-lowering drugs (n=43 per group, p < 0.05).

Original Statement

“Patients treated with SGLT-2i had lower circulating levels of IL-6, a prototypical marker of LGI, but also of uric acid and fasting insulin, compared with patients treated with other GLD.”

From study:Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin

Evidence Quality Assessment

Claim Status

appropriately stated

Study Design Support

Design supports claim

Appropriate Language Strength

association

Can only show association/correlation

Assessment Explanation

Observational study design only supports association. 'Associated with' appropriately reflects the evidence.

Evidence from Studies

Supporting (1)

Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin

Cross-Sectional Study

Human

2022 May 3

Contradicting (0)

No contradicting evidence found

Source Study

Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin

Score: 49

DOI: 10.1007/s00018-022-04289-z

Similar Assertions

People with type 2 diabetes who take SGLT-2 inhibitors tend to have lower fasting insulin levels than those using other diabetes drugs.

85%

People with type 2 diabetes who take SGLT-2 inhibitors tend to have lower levels of a key inflammation marker called interleukin-6 than those taking other diabetes medications.

80%